Formats
  1. Journal Article (66871)
  2. Meeting Abstract (33621)
  3. Book Section (5097)
  4. Review (3759)
  5. Editorial (2172)
  6. Conference Paper (1526)
  7. Correspondence (666)
  8. Guidelines (662)
  9. Research Letter (548)
  10. Book Whole (344)
  11. Miscellaneous (339)
Groups
  1. Department of Medicine (39065)
  2. GSK Faculty (22476)
  3. Solid Tumor Oncology Division (22077)
  4. Surgery (21270)
  5. Survivorship Research (15773)
  6. Sloan Kettering Institute Faculty (15657)

More Groups

People
  1. Marc Ladanyi (1328)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1052)

More People

Years
  1. 2025 (2137)
  2. 2024 (5384)
  3. 2023 (5806)
  4. 2022 (6169)
  5. 2021 (5714)
  6. 2020 (5618)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4951)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2611)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1814)

More Publications

Publishers
  1. Elsevier Inc. (13846)
  2. American Society of Clinical Oncology (9169)
  3. Springer (7194)
  4. Nature Publishing Group (6375)
  5. American Association for Cancer Research (6014)
  6. Elsevier Science, Inc. (5512)

More Publishers

Results (115605)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Initial results from SELECT-AML-1, a Phase 2 Study of tamibarotene in combination with venetoclax and azacitidine in RARA-positive newly diagnosed AML patients ineligible for standard induction chemotherapy
    Meeting Abstract

    Kambhampati, S.; McMahon, C. M.; Eghtedar, A.; Pollyea, D. A.; de Botton, S.; Pigneux, A.; Cherry, M.; Ball, B. J.; Borthakur, G.; Cluzeau, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • RNA deadenylation subunit CNOT3 promotes myeloid leukemia by driving translation of oncogenic targets
    Meeting Abstract

    Ghashghaei, M.; Yue, M.; Arsalan, A.; Bombaci, G.; Miko, S. S.; Shaalan, H.; Edin, G.; Morin, G.; Perna, F.; Vu, L. P.
    Blood (2022)

    Fulltext@MSK | Save
  • Fructose treatment targets myeloid leukemogenesis in IDH2 mutants by exhausting alpha-ketoglutarate pools
    Meeting Abstract

    Savino, A. M.; Turner, B.; Jeong, S.; Schild, T.; Yang, X.; Luo, H.; Chirayil, R.; Cullen, Q.; Chan, M.; Han, G.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage
    Meeting Abstract

    Vekariya, U. M.; Sullivan-Reed, K.; Toma, M.; Nieborowska-Skorska, M.; Le, B. V.; Caron, M. C.; Kukuyan, A. M.; Podszywalow-Bartnicka, P.; Chitrala, K.; Atkins, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Transient M-proteins: Epidemiology, causes, and the impact of mass spectrometry: The iStopMM study
    Meeting Abstract

    Palmason, R.; Berlanga, O.; Sigurdsson, J. K.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Ekberg, S.; Crowther, M.; Levy, M.; Reed, E. R.; Þórir Oskarsson, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
    Meeting Abstract

    Korde, N.; Diamond, B.; Burge, M.; Hassoun, H.; Landau, H.; Hultcrantz, M.; Mailankody, S.; Maclachlan, K. H.; Shah, U. A.; Derkach, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The characteristics and prognosis of patients with clonal cytopenias of undetermined significance, including cancer and therapy-related clonal cytopenias
    Meeting Abstract

    Xie, Z.; Smith, A.; Komrokji, R. S.; Al Ali, N.; Patel, A. A.; Saygin, C.; Zeidan, A. M.; Bewersdorf, J. P.; Kishtagari, A.; Zeidner, J. F.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma: Phase 1b results of SYMPHONY-1
    Meeting Abstract

    Batlevi, C. L.; Salles, G.; Park, S. I.; Phillips, T. J.; Amengual, J. E.; Andorsky, D.; Campbell, P.; McKay, P.; Leonard, J. P.; Sondhi, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from the phase 1/2 BRUIN study
    Meeting Abstract

    Mato, A. R.; Woyach, J. A.; Brown, J. R.; Ghia, P.; Patel, K.; Eyre, T. A.; Munir, T.; Lech-Maranda, E.; Lamanna, N.; Tam, C. S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • NX-2127-001, first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies
    Meeting Abstract

    Mato, A. R.; Wierda, W. G.; Ai, W. Z.; Flinn, I. W.; Tees, M.; Patel, M. R.; Patel, K.; O'Brien, S.; Bond, D. A.; Roeker, L. E.; more...
    Blood (2022)

    Fulltext@MSK | Save